Cancer Research

{
  "result": " This tick produced no new empirical findings, yet its most important output was a deliberate act of scientific triage: the swarm recognized that its knowledge graph had grown to 151 disconnected entities with zero hardened causal relations, diluted by off-topic reviews ranging from heart-failure remote monitoring to shoulder-balance prediction. Rather than continue accumulating disconnected facts, the mission executed a hard pivot, concentrating all compute on a single, medically tantalizing question—whether PCSK9, the protein target of widely used cholesterol-lowering drugs, plays a causally distinct role in microsatellite-stable (MSS) versus microsatellite-unstable (MSI) colorectal cancer.\n\nColorectal cancer is not biologically uniform. MSS tumors typically retain DNA mismatch repair proficiency and often present as immunologically “cold,” whereas MSI tumors are mismatch-repair deficient, hypermutated, and immunologically “hot.” If PCSK9 levels influence cancer risk or viability differently across these subtypes, drugs already approved for cardiovascular disease could, in principle, be repurposed with precision. But correlation is not causation. To test this, the swarm launched a three-pillar orthogonal validation framework. First, cis-pQTL Mendelian randomization—using strict genetic instruments near the PCSK9 gene that alter its blood protein levels (independent variants selected by LD-clumping at r² < 0.001 and robust F-statistics > 10)—to ask whether inherited variation in PCSK9 changes CRC risk differently in MSS and MSI strata across massive genome-wide association datasets. Second, tumor-tissue eQTL colocalization to determine whether the same DNA variant at the 1p34.1–1p32.3 locus drives both PCSK9 expression in actual CRC tumors and overall CRC risk. Third, analysis of DepMap CRISPR knockout screens to test whether PCSK9 loss is differentially essential in mismatch-repair-deficient versus proficient colorectal cancer cell lines, adjusting for mutation burden and genetic lineage.\n\nBecause zero new relations were added this tick, the relation count remains at zero; the three updated hypotheses reflect sharpened methodological criteria rather than discovered biological effects. Off-topic entities were permanently archived, clearing the workspace for the mandated triad. While this lack of immediate results may appear to be stasis, it embodies the unglamorous discipline required for credible discovery: ensuring that the next edge entering the graph survives rigorous, multi-modal scrutiny rather than wishful thinking.\n\nThe open questions are now razor-sharp. Will the cis-pQTL instruments for PCSK9 survive colocalization with the protein signal and yield directionally consistent Mendelian randomization estimates across at least two independent proteomic studies? If a genetic effect emerges, does the tumor eQTL share a causal variant with CRC risk, with the expression-altering allele matching the MR-predicted risk direction? And will the DepMap essentiality data mirror that same directional story? The swarm will not broaden its search to other therapeutic candidates or disease areas until this specific PCSK9–CRC edge either satisfies all three hardened criteria or fails definitively. We are hopeful that this concentration of force will soon convert hypothesis into evidence.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}